1. Home
  2. INCY vs WPC Comparison

INCY vs WPC Comparison

Compare INCY & WPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INCY
  • WPC
  • Stock Information
  • Founded
  • INCY 1991
  • WPC 1973
  • Country
  • INCY United States
  • WPC United States
  • Employees
  • INCY N/A
  • WPC N/A
  • Industry
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • WPC Real Estate Investment Trusts
  • Sector
  • INCY Health Care
  • WPC Real Estate
  • Exchange
  • INCY Nasdaq
  • WPC Nasdaq
  • Market Cap
  • INCY 17.0B
  • WPC 14.7B
  • IPO Year
  • INCY 1993
  • WPC 1998
  • Fundamental
  • Price
  • INCY $91.48
  • WPC $66.93
  • Analyst Decision
  • INCY Buy
  • WPC Hold
  • Analyst Count
  • INCY 19
  • WPC 9
  • Target Price
  • INCY $81.73
  • WPC $111.88
  • AVG Volume (30 Days)
  • INCY 1.7M
  • WPC 980.0K
  • Earning Date
  • INCY 10-28-2025
  • WPC 10-28-2025
  • Dividend Yield
  • INCY N/A
  • WPC 5.39%
  • EPS Growth
  • INCY 900.04
  • WPC N/A
  • EPS
  • INCY 4.37
  • WPC 1.52
  • Revenue
  • INCY $4,584,996,000.00
  • WPC $1,636,111,000.00
  • Revenue This Year
  • INCY $16.41
  • WPC $7.46
  • Revenue Next Year
  • INCY $10.86
  • WPC $3.36
  • P/E Ratio
  • INCY $20.90
  • WPC $43.91
  • Revenue Growth
  • INCY 18.87
  • WPC N/A
  • 52 Week Low
  • INCY $53.56
  • WPC $52.91
  • 52 Week High
  • INCY $92.86
  • WPC $69.79
  • Technical
  • Relative Strength Index (RSI)
  • INCY 67.77
  • WPC 43.69
  • Support Level
  • INCY $84.38
  • WPC $67.00
  • Resistance Level
  • INCY $92.86
  • WPC $68.54
  • Average True Range (ATR)
  • INCY 2.44
  • WPC 1.01
  • MACD
  • INCY 0.35
  • WPC -0.11
  • Stochastic Oscillator
  • INCY 86.26
  • WPC 13.97

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About WPC W. P. Carey Inc. REIT

W.P. Carey Inc is a real estate investment trust principally involved in the ownership of properties located in the U.S., Western Europe, and Northern Europe. W.P. Carey organizes its operations into Real Estate and Investment Management segments. The vast majority of the company's income is derived from its Real Estate division in the form of lease revenue from long-term agreements with companies. W.P. Carey's real estate portfolio is primarily comprised of single-tenant office, industrial, warehouse, and retail facilities located around the world. majority of the company's revenue comes from properties in the USA. Its Investment Management unit generates revenue from providing real estate advisory and portfolio management services to other REITs.

Share on Social Networks: